Treatment plan optimization and robustness of <sup>106</sup>Ru eye plaque brachytherapy using a novel software tool.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28185660.
- Also identified by DOI 10.1016/j.radonc.2017.01.010.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To analyze treatment plan robustness and plan optimization strategies of <sup>106</sup>Ru eye plaque brachytherapy using a novel software tool. A treatment planning software was developed that allows to calculate dose-volume metrics. Plaque misplacements were simulated and evaluated with respect to the effect on tumor coverage and dose changes in critical structures. Two treatment plan optimization approaches were analyzed: (a) reducing plaque size and (b) shifting the plaque away from organs-at-risk (OAR). Maximum tumor sizes were identified which can be covered by the prescribed dose for different robustness levels (0-2mm). For an apex height of 5mm a 1mm uncertainty yielded changes in D<sub>2%</sub> to the lens of up to ±13Gy in anterior and ±20Gy to the optic nerve in posterior tumors. By reducing the plaque size D<sub>mean</sub> and D<sub>2%</sub> to lens, optic nerve and macula were decreased by >60% for most simulated cases. Similarly, by shifting the plaque away from the lens dose reductions of 15%/mm in anterior and even 30%/mm in central tumors were achieved. Critical structures in the treatment of uveal melanomas with <sup>106</sup>Ru plaques can benefit from the proposed, computational treatment plan optimization.
Medical subject headings
- Brachytherapy
- Melanoma
- Radiotherapy Planning, Computer-Assisted
- Ruthenium Radioisotopes
- Software
- Uveal Neoplasms